Is ARTV or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Kailera Therapeutics N/A N/A N/A

Does the media favor ARTV or KLRA?

In the previous week, Artiva Biotherapeutics had 9 more articles in the media than Kailera Therapeutics. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 9 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.18 beat Artiva Biotherapeutics' score of 0.10 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kailera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is ARTV or INBX more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Inhibrx Biosciences N/A -563.90% -83.48%

Does the media prefer ARTV or INBX?

In the previous week, Artiva Biotherapeutics had 15 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 3 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.34 beat Artiva Biotherapeutics' score of 0.10 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is OMER or ARTV more profitable?

Artiva Biotherapeutics' return on equity of -53.86% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -164.92% 69.41% Artiva Biotherapeutics N/A -53.86% -48.16%

Does the media favor OMER or ARTV?

In the previous week, Artiva Biotherapeutics had 14 more articles in the media than Omeros. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 4 mentions for Omeros. Artiva Biotherapeutics' average media sentiment score of 0.10 beat Omeros' score of -0.24 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Artiva Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ARTV or COAG more profitable?

Hemab Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Hemab Therapeutics N/A N/A N/A

Does the media refer more to ARTV or COAG?

In the previous week, Artiva Biotherapeutics had 15 more articles in the media than Hemab Therapeutics. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Artiva Biotherapeutics' score of 0.10 indicating that Hemab Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Hemab Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ARTV or NBTX?

Nanobiotix has higher revenue and earnings than Artiva Biotherapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artiva Biotherapeutics $250K 1,357.19 -$83.86M -$3.30 N/A Nanobiotix $36.87M 32.51 -$27.11M N/A N/A

Is ARTV or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Artiva Biotherapeutics N/A -53.86% -48.16% Nanobiotix N/A N/A N/A

Does the media refer more to ARTV or NBTX?

In the previous week, Artiva Biotherapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 2 mentions for Nanobiotix. Artiva Biotherapeutics' average media sentiment score of 0.10 beat Nanobiotix's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artiva Biotherapeutics 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Artiva Biotherapeutics (ARTV) Competitors

$6.94 +0.14 (+2.06%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.92 -0.03 (-0.36%)

As of 10/9/2026 07:30 PM Eastern

Compare

ARTV vs. KLRA, INBX, OMER, COAG, and NBTX

Should you buy Artiva Biotherapeutics stock or one of its competitors? Artiva Biotherapeutics's main competitors and comparable companies include Kailera Therapeutics (KLRA), Inhibrx Biosciences (INBX), Omeros (OMER), Hemab Therapeutics (COAG), and Nanobiotix (NBTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Artiva Biotherapeutics compare to Kailera Therapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Kailera Therapeutics (NASDAQ:KLRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

In the previous week, Artiva Biotherapeutics had 9 more articles in the media than Kailera Therapeutics. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 9 mentions for Kailera Therapeutics. Kailera Therapeutics' average media sentiment score of 0.18 beat Artiva Biotherapeutics' score of 0.10 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kailera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Artiva Biotherapeutics presently has a consensus target price of $39.00, suggesting a potential upside of 461.96%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 268.22%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Artiva Biotherapeutics is more favorable than Kailera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Kailera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Artiva Biotherapeutics has higher revenue and earnings than Kailera Therapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Kailera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,357.19	-$83.86M	-$3.30	N/A
Kailera Therapeutics	N/A	N/A	-$148.96M	-$3.65 thousand	N/A

Kailera Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Kailera Therapeutics	N/A	N/A	N/A

Summary

Artiva Biotherapeutics beats Kailera Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Inhibrx Biosciences?

Artiva Biotherapeutics (NASDAQ:ARTV) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.81, meaning that its stock price is 281% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 1.8% of Artiva Biotherapeutics shares are owned by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Artiva Biotherapeutics' return on equity of -53.86% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Artiva Biotherapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Artiva Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,357.19	-$83.86M	-$3.30	N/A
Inhibrx Biosciences	$1.30M	1,075.81	-$140.05M	-$8.88	N/A

In the previous week, Artiva Biotherapeutics had 15 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 3 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 0.34 beat Artiva Biotherapeutics' score of 0.10 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics currently has a consensus target price of $39.00, indicating a potential upside of 461.96%. Inhibrx Biosciences has a consensus target price of $197.50, indicating a potential upside of 107.87%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Artiva Biotherapeutics beats Inhibrx Biosciences on 10 of the 15 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Omeros?

Omeros (NASDAQ:OMER) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Artiva Biotherapeutics' return on equity of -53.86% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-164.92%	69.41%
Artiva Biotherapeutics	N/A	-53.86%	-48.16%

Omeros presently has a consensus target price of $34.00, suggesting a potential upside of 71.46%. Artiva Biotherapeutics has a consensus target price of $39.00, suggesting a potential upside of 461.96%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 1.8% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Omeros has higher earnings, but lower revenue than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	N/A	N/A	-$3.35M	$1.28	15.49
Artiva Biotherapeutics	$250K	1,357.19	-$83.86M	-$3.30	N/A

In the previous week, Artiva Biotherapeutics had 14 more articles in the media than Omeros. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 4 mentions for Omeros. Artiva Biotherapeutics' average media sentiment score of 0.10 beat Omeros' score of -0.24 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Artiva Biotherapeutics	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Omeros has a beta of 2.57, meaning that its stock price is 157% more volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.4, meaning that its stock price is 140% more volatile than the broader market.

Summary

Omeros and Artiva Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Hemab Therapeutics?

Artiva Biotherapeutics (NASDAQ:ARTV) and Hemab Therapeutics (NASDAQ:COAG) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Hemab Therapeutics has lower revenue, but higher earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,357.19	-$83.86M	-$3.30	N/A
Hemab Therapeutics	N/A	N/A	N/A	-$24.78	N/A

Hemab Therapeutics' return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Hemab Therapeutics	N/A	N/A	N/A

In the previous week, Artiva Biotherapeutics had 15 more articles in the media than Hemab Therapeutics. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 3 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Artiva Biotherapeutics' score of 0.10 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Hemab Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Artiva Biotherapeutics currently has a consensus price target of $39.00, suggesting a potential upside of 461.96%. Hemab Therapeutics has a consensus price target of $51.40, suggesting a potential upside of 62.56%. Given Artiva Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Artiva Biotherapeutics is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Hemab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Artiva Biotherapeutics beats Hemab Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Artiva Biotherapeutics compare to Nanobiotix?

Artiva Biotherapeutics (NASDAQ:ARTV) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

38.8% of Nanobiotix shares are held by institutional investors. 1.8% of Artiva Biotherapeutics shares are held by company insiders. Comparatively, 3.5% of Nanobiotix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Artiva Biotherapeutics had 16 more articles in the media than Nanobiotix. MarketBeat recorded 18 mentions for Artiva Biotherapeutics and 2 mentions for Nanobiotix. Artiva Biotherapeutics' average media sentiment score of 0.10 beat Nanobiotix's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Artiva Biotherapeutics	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix has higher revenue and earnings than Artiva Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artiva Biotherapeutics	$250K	1,357.19	-$83.86M	-$3.30	N/A
Nanobiotix	$36.87M	32.51	-$27.11M	N/A	N/A

Artiva Biotherapeutics currently has a consensus price target of $39.00, suggesting a potential upside of 461.96%. Nanobiotix has a consensus price target of $46.67, suggesting a potential upside of 97.07%. Given Artiva Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Artiva Biotherapeutics is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nanobiotix's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artiva Biotherapeutics	N/A	-53.86%	-48.16%
Nanobiotix	N/A	N/A	N/A

Artiva Biotherapeutics has a beta of 2.4, indicating that its share price is 140% more volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Summary

Artiva Biotherapeutics beats Nanobiotix on 7 of the 13 factors compared between the two stocks.

Get Artiva Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTV vs. The Competition

Export

Metric	Artiva Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$332.45M	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.37%
P/E Ratio	-2.10	13.42	274.15	26.16
Price / Sales	1,357.19	1,234.32	589.97	94.50
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	1.55	17.17	11.21	6.34
Net Income	-$83.86M	-$22.69M	$3.50B	$381.90M
7 Day Performance	1.61%	-1.33%	-0.90%	-1.41%
1 Month Performance	-33.40%	-8.44%	-4.44%	-3.48%
1 Year Performance	146.98%	14.02%	6.96%	1.16%

Artiva Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTV Artiva Biotherapeutics	3.3303 of 5 stars	$6.94 +2.1%	$39.00 +462.0%	+131.3%	$332.45M	$250K	N/A	115	News Coverage Insider Trade
KLRA Kailera Therapeutics	2.2173 of 5 stars	$10.83 -0.1%	$42.75 +294.7%	N/A	$1.40B	N/A	N/A	145	Analyst Downgrade Lockup Expiration
INBX Inhibrx Biosciences	3.4865 of 5 stars	$93.41 -1.2%	$197.50 +111.4%	+171.5%	$1.37B	N/A	N/A	110
OMER Omeros	3.8852 of 5 stars	$18.51 -2.1%	$34.00 +83.7%	+334.9%	$1.34B	$38.42M	14.46	175	Analyst Upgrade
COAG Hemab Therapeutics	2.7256 of 5 stars	$28.37 -7.3%	$51.40 +81.2%	N/A	$1.33B	N/A	N/A	59

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTV) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. KLRA, INBX, OMER, COAG, and NBTX

How does Artiva Biotherapeutics compare to Kailera Therapeutics?

Summary

How does Artiva Biotherapeutics compare to Inhibrx Biosciences?

Summary

How does Artiva Biotherapeutics compare to Omeros?

Summary

How does Artiva Biotherapeutics compare to Hemab Therapeutics?

Summary

How does Artiva Biotherapeutics compare to Nanobiotix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artiva Biotherapeutics (ARTV) Competitors

ARTV vs. KLRA, INBX, OMER, COAG, and NBTX

How does Artiva Biotherapeutics compare to Kailera Therapeutics?

Does the media favor ARTV or KLRA?

Do analysts recommend ARTV or KLRA?

Which has stronger valuation and earnings, ARTV or KLRA?

Is ARTV or KLRA more profitable?

Summary

How does Artiva Biotherapeutics compare to Inhibrx Biosciences?

Which has more volatility & risk, ARTV or INBX?

Do institutionals & insiders have more ownership in ARTV or INBX?

Is ARTV or INBX more profitable?

Which has better valuation & earnings, ARTV or INBX?

Does the media prefer ARTV or INBX?

Do analysts recommend ARTV or INBX?

Summary

How does Artiva Biotherapeutics compare to Omeros?

Is OMER or ARTV more profitable?

Do analysts rate OMER or ARTV?

Do insiders and institutionals hold more shares of OMER or ARTV?

Which has higher earnings & valuation, OMER or ARTV?

Does the media favor OMER or ARTV?

Which has more volatility & risk, OMER or ARTV?

Summary

How does Artiva Biotherapeutics compare to Hemab Therapeutics?

Which has stronger earnings and valuation, ARTV or COAG?

Is ARTV or COAG more profitable?

Does the media refer more to ARTV or COAG?

Do analysts rate ARTV or COAG?

Summary

How does Artiva Biotherapeutics compare to Nanobiotix?

Do insiders & institutionals believe in ARTV or NBTX?

Does the media refer more to ARTV or NBTX?

Which has better earnings & valuation, ARTV or NBTX?

Do analysts rate ARTV or NBTX?

Is ARTV or NBTX more profitable?

Which has more volatility and risk, ARTV or NBTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTV vs. The Competition

Artiva Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools